"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

Bleeding is a clinically significant issue with all current anticoagulants. Safer antithrombotic strategies are required. Click to show full abstract

Bleeding is a clinically significant issue with all current anticoagulants. Safer antithrombotic strategies are required.

Keywords: first randomized; evaluation safety; randomized evaluation; pharmacodynamics pharmacokinetics; safety pharmacodynamics; factor

Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2022

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended